Form 4: OmniAb Director Jennifer Cochran Increases Stake Through RSU Vesting and New Equity Grants

OmniAb, Inc. Director Jennifer R. Cochran reported an increase in her beneficial ownership of common stock following the vesting of restricted stock units and the grant of new equity awards.

Summary

• Jennifer R. Cochran, a Director of OmniAb, Inc. (OABI), reported changes in her beneficial ownership of company securities.
• On June 17, 2025, 20,000 Restricted Stock Units (RSUs) vested, converting into 20,000 shares of Common Stock.
• Following this transaction, Ms. Cochran's direct beneficial ownership of Common Stock increased to 165,274 shares.
• Additionally, Ms. Cochran was granted 20,000 new Restricted Stock Units (RSUs) and 40,000 Stock Options.
• The newly granted RSUs and Stock Options will vest in full on the earlier of the next annual meeting of stockholders or the first anniversary of their grant date.
• The Stock Options have an exercise price of $1.7 per share and expire on June 17, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased beneficial ownership and continued equity compensation, which is generally a positive signal of alignment with shareholder interests, though it's a routine transaction.

Positives

• Director Jennifer R. Cochran increased her direct beneficial ownership of Common Stock to 165,274 shares, aligning her interests with shareholders.
• The grant of new Restricted Stock Units (20,000) and Stock Options (40,000) indicates continued equity-based compensation for the director, reinforcing long-term commitment.

Future Outlook

The document indicates that newly granted Restricted Stock Units and Stock Options will vest on the earlier of the next annual meeting of stockholders or the first anniversary of their grant date, suggesting future equity accumulation for the director.

Industry Context

This is a standard insider transaction filing, reflecting common practices of executive and director compensation through equity awards in publicly traded companies, particularly in sectors like biotechnology or pharmaceuticals, which OmniAb operates in.

Comparison to Industry Standards

• Equity compensation, including Restricted Stock Units (RSUs) and stock options, is a standard practice for directors and executives across publicly traded companies, especially in high-growth sectors like biotech.
• The specific amounts and vesting schedules detailed in the filing are typical for aligning long-term interests of directors with shareholder value.

Related Party Transactions

• The equity grants (Restricted Stock Units and Stock Options) are related party transactions as they involve compensation from the company to a director, which is a standard practice for executive and director remuneration.

Stakeholder Impact

• Shareholders: The increase in director ownership and continued equity compensation aligns the director's interests with shareholders, potentially signaling confidence in the company's future performance.
• Employees/Management: Reflects standard equity compensation practices for key personnel, which can be a positive for morale and retention.

Next Steps

• Future vesting of the newly granted 20,000 RSUs and 40,000 Stock Options on the earlier of the next annual meeting or the first anniversary of the grant date.

Key Dates

Keywords

OmniAb, OABI, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director, Jennifer R. Cochran